Drug Pipeline

Giredestrant Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
15
Active Studies
6
Recruiting
6
Phase 3
4
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT04961996
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With…
date change Completion moved earlier: 2035-01-01 -> 2033-09-30
2026-05-19 NCT07100106
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant…
Trial sites expanded: 35 -> 39 locations
2026-05-16 NCT03332797
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing…
date change Primary completion pushed: 2026-07-31 -> 2027-07-31
2026-05-16 NCT03332797
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing…
date change Completion pushed: 2026-07-31 -> 2027-07-31
Active Studies by Phase
Phase 3
6
Phase 2
4
Phase 1/2
3
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting
NCT05296798 A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo… Locally Advanced or Metastatic Breast Cancer Active, Not Recruiting
NCT05306340 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With… Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer Active, Not Recruiting
NCT04546009 A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib… Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Active, Not Recruiting
NCT07541079 A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant… Early Breast Cancer Not Yet Recruiting
NCT04961996 A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With… Early Breast Cancer Active, Not Recruiting
Phase 2
NCT05708235 A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in… Breast Cancer Recruiting
NCT04576455 A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's… Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Active, Not Recruiting
NCT05634499 A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer Endometrial Cancer Active, Not Recruiting
NCT04931342 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With… Ovarian Cancer Active, Not Recruiting
Phase 1/2
NCT04486352 A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Endometrial Cancer Recruiting
NCT07100106 A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant… Breast Cancer Recruiting
NCT04802759 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in… Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Recruiting
Phase 1
NCT07214662 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… Breast Cancer Recruiting
NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing… Breast Cancer Active, Not Recruiting
Sponsors Running Giredestrant Trials
Disease Areas
Get alerts when Giredestrant trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free